Compare MTRX & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTRX | TENX |
|---|---|---|
| Founded | 1984 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.0M | 317.8M |
| IPO Year | 1995 | 2001 |
| Metric | MTRX | TENX |
|---|---|---|
| Price | $11.33 | $15.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $17.00 | ★ $29.67 |
| AVG Volume (30 Days) | 175.1K | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $769,286,000.00 | N/A |
| Revenue This Year | $19.75 | N/A |
| Revenue Next Year | $7.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.64 | N/A |
| 52 Week Low | $9.88 | $5.80 |
| 52 Week High | $15.97 | $19.40 |
| Indicator | MTRX | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 30.67 | 49.50 |
| Support Level | $10.71 | $13.13 |
| Resistance Level | $12.62 | $16.35 |
| Average True Range (ATR) | 0.49 | 1.20 |
| MACD | -0.10 | -0.22 |
| Stochastic Oscillator | 4.38 | 19.03 |
Matrix Service Co provides engineering, fabrication, construction, maintenance, and repair services prominently to the energy and industrial markets. The company operates through three main segments: Storage and Terminal Solutions, Utility and Power Infrastructure, and Process and Industrial Facilities. These segments cover services like building and maintaining storage tanks and terminals, supporting power delivery and new power generation projects including renewables, as well as plant maintenance and turnarounds for refining and petrochemical industries. Matrix generates revenue by delivering these services to clients in oil, gas, power, and petrochemical sectors across North America and internationally.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.